ESC 2016: Utilizing PCSK9 Therapies for Better Long-Term Outcomes in Dyslipidemia Patients
This CME Program will highlight information presented at the European Society of Cardiology Congress 2016 held in Rome, Italy on August 27-31, 2016. Didactic presentation in combination with intermittent, interactive panel discussions will provide clinicians with a better understanding of the pathophysiology of hypercholesterolemia, including approaches for prevention and assessment of risk. Three expert faculty will decipher recent clinical trial data and communicate new treatment strategies, including those centered around PCSK9 usage, as well as best practices for patients with dyslipidemia. Discussion about the role and importance of the comprehensive healthcare team will ensue. Upon completing this program, clinicians responsible for the management of patients with dyslipidemia will be better equipped with the most up-to-date information to create tailored treatment plans and optimize patient outcomes.
This activity has been designed to meet the educational needs of cardiologists, endocrinologists, primary care physicians, and other healthcare professionals responsible for the diagnosis, treatment or management of patients with dyslipidemia.
Upon completion of this activity, participants will be able to:
- Describe the pathophysiology of hypercholesterolemia, including risk assessment and preventive strategies for cardiovascular disease.
- Examine clinical trial data for emerging PCSK9 inhibitors for the treatment of dyslipidemia presented at ESC 2016.
- Integrate new data into individualized treatment plans to improve and maintain outcomes for patients with dyslipidemia.
Christopher P. Cannon, MD
Robert P. Giugliano, MD
Sekar Kathiresan, MD
James Underberg, MD
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Faculty||Relationship Identified With:|
|Christopher Cannon, MD|
Consultant/Advisor: Alnylam Pharmaceuticals, Inc.; Amgen Inc.; Arisaph Pharmaceuticals, Inc.; Boehringer Ingelheim GmbH ; Bristol-Myers Squibb Company; Eli Lilly and Company; GlaxoSmithKline plc.; Kowa Pharmaceuticals America, Inc.; LipoMedix; Merck & Co., Inc.; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; sanofi-aventis U.S. LLC; Takeda Pharmaceuticals U.S.A., Inc.
Grant/Research Support: Arisaph Pharmaceuticals, Inc.; AstraZeneca; Boehringer Ingelheim GmbH; Bristol-Myers Squibb Company; GlaxoSmithKline plc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Takeda Pharmaceuticals U.S.A., Inc.
Robert P. Giugliano, MD
Consultant/Advisor: Amarin Corp.; American College of Cardiology Foundation; Amgen Inc.; Boehringer Ingelheim GmbH; Bristol-Myers Squibb Company; CVS/caremark; Daiichi Sankyo, Inc.; GlaxoSmithKline plc.; Lexicon Pharmaceuticals, Inc.; Merck & Co., Inc.; Portola Pharmaceuticals, Inc.; Pfizer Inc.; St. Jude Children’s Research Hospital; Stealth BioTherapeutics Inc.
Grant/Research Support: Amgen Inc.
Speaker's Bureau: Amgen Inc.; Daiichi Sankyo, Inc.; Merck & Co., Inc.
Sekar Kathiresan, MD
Consultant/Advisor: Alnylam Pharmaceuticals, Inc.; AstraZeneca; Bayer AG; Catabasis Pharmaceuticals, Inc.; Celera Corporation; Eli Lilly and Company; Genomics plc; Ionis Pharmaceuticals, Inc.; Leerink Partners LLC; Merck & Co., Inc.; Noble Insights; Novartis AG; Regeneron Pharmaceuticals, Inc.; sanofi-aventis U.S. LLC
Grant/Research Support: Bayer AG; Regeneron Pharmaceuticals, Inc.
Stock Ownership: Catabasis Pharmaceuticals, Inc.; San Therapeutics
|James Underberg, MD|
Consultant/Advisor: Aegerion Pharmaceuticals, Inc.; Akcea Therapeutics; Amarin Corp.; Amgen Inc.; Invitae Corporation; National Lipid Association; Recombine
Grant/Research Support: Aegerion Pharmaceuticals Inc.; Pfizer Inc.Speaker's Bureau: Alexion; Amgen Inc.; AstraZeneca; Genzyme Corporation; Merck & Co., Inc.; Regeneron Pharmaceuticals, Inc.; sanofi-aventis U.S. LLC; True Health Diagnostics
Non-faculty: Sandra Breslow; Alison Kemp; Leah Johnson; Timothy Hayes, MD, PhD; Emma Gilmartin; Nicole Brestowski and Bernard M. Abrams, MD hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
This CME activity has been supported by an independent educational grant from Amgen Inc.
Co-provided by the Elsevier Office of Continuing Medical Education and AcademicCME.
CME Credit (Physicians)
The Elsevier Office of Continuing Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credit™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at firstname.lastname@example.org. Additional information on the process of converting AMA PRA Category 1 Credits™ to ECMECs® can be found at: www.eaccme.eu.
AANP Credit (Nurse Practitioners)
This activity is approved for 1.0 contact hour(s) of continuing education by the American Association of Nurse Practitioners. Activity ID 16102403. This activity was planned in accordance with the AANP CE Standards and Policies.
CME INQUIRIES/SPECIAL NEEDS
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Elsevier Office of Continuing Medical Education, AcademicCME and Amgen Inc. do not recommend the use of any agent outside of the labeled indications.
Disclaimer Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 1.00 AANP
- 1.00 AMA PRA Category 1 Credit(s)™
- 1.00 Non-physician